Anastrozole (Arimidex) — what it does, evidence, and safety

What it is

Anastrozole (brand name Arimidex) is best known as a breast cancer treatment for postmenopausal women, lowering estrogen by blocking the aromatase enzyme that converts androgens into estrogen. It's a small-molecule oral tablet, not a peptide. It's FDA-approved specifically for that use; off-label, it's also used in men (for example alongside testosterone therapy) to control estrogen, though that use isn't FDA-approved.

What the research found

Anastrozole is used mainly to treat breast cancer in postmenopausal women, and studied off-label in men to lower estrogen. It's FDA-approved for the breast-cancer use. In large trials in postmenopausal women with breast cancer, it improved disease-free survival. In men, smaller randomized trials found it reliably raised testosterone and lowered estradiol, but a 12-month placebo-controlled trial found no improvement in body composition, strength, or other clinical measures, so the hormone effect is well established while the clinical benefit in men is not.

Status and regulatory position

FDA-approved as Arimidex (anastrozole) tablets, NDA 020541 — originally approved December 27, 1995, for treatment of advanced breast cancer in postmenopausal women; subsequent expansions to first-line therapy of postmenopausal hormone-receptor-positive locally advanced or metastatic breast cancer (2000) and adjuvant treatment of early-stage hormone-receptor-positive breast cancer in postmenopausal women (2005, ATAC-trial-supported).[¹] Generic anastrozole became available in 2010 following patent expiration; multiple generic manufacturers now supply tablets. The FDA-approved indications are exclusively in postmenopausal women — anastrozole is not FDA-approved for any male indication. Off-label use in men with hypogonadism, infertility, or as a TRT-adjunct to suppress aromatization-driven estradiol elevation is widespread but operates outside FDA approval and outside any of the men's-health professional-society guidelines (Endocrine Society, AUA). Not DEA-scheduled. WADA-banned in regulated sport — explicitly named under Section S4.1 (Aromatase Inhibitors) of the 2026 Prohibited List as a Specified Substance.

Safety

Anastrozole is a prescription-only medication, FDA-approved only for breast cancer in postmenopausal women; it is banned in WADA-tested sport, and over-suppression of estrogen carries its own risks (such as bone loss and joint pain). VialWise is a research and educational reference, not medical advice — consult a licensed professional.

Disclosures

⚠️ For research and educational purposes only. Anastrozole (Arimidex) is FDA-approved exclusively for treatment of breast cancer in postmenopausal women. Use in men — for hypogonadism, infertility, or as a TRT-adjunct — is off-label and operates outside FDA approval. Information in this entry is informational, not medical advice. Always consult appropriate professional guidance before any protocol decisions.

⚠️ Anastrozole is not a peptide. This entry exists in the Vialwise library because researchers running peptide protocols and TRT (see [testosterone.md](./testosterone.md)) frequently use anastrozole as a TRT-adjunct to suppress estradiol elevation driven by aromatization of supplemental testosterone. The compound is a small-molecule non-steroidal aromatase inhibitor (molecular weight 293 Da) — not a peptide, not a protein, not an injectable. It is taken as an oral film-coated tablet, with no reconstitution and no syringe involved. Mechanistically, pharmacologically, and regulatorily it sits in a different category from the rest of the Vialwise library.

⚠️ The Vialwise calculator is informational, not computational, for anastrozole. Unlike injectable peptides where the calculator computes draws from concentration math, anastrozole is dosed as whole or split tablets (or). The calculator's role for anastrozole is to display the labeled and off-label dosing patterns plus the pill-splitting precision considerations — there is no per-injection draw to compute. Researchers who use anastrozole alongside injectable peptide protocols will use the calculator only for the injectable components.

⚠️ Pill splitting precision matters at sub-1-mg doses. Off-label research-community use commonly targets per dose (vs the FDA-label for breast cancer). Achieving requires splitting a tablet in half; achieving requires splitting into quarters. Anastrozole tablets are not score-marked, and unscored split tablets vary substantially in dose accuracy — published pill-splitting studies show 10–30% dose variation between halves of unscored tablets. For quartered doses, the variation can exceed 50%. Researchers using sub-1-mg doses should be explicit with themselves about the precision-vs-convenience tradeoff and consider pharmacy-compounded sub-1-mg capsules where available. Anastrozole is also dosed by frequency rather than by per-dose precision — twice weekly delivers the same total exposure as four times weekly with materially different peak-trough profiles given anastrozole's ~50-hour half-life.

⚠️ WADA-banned in regulated sport — explicitly named under Section S4.1 (Aromatase Inhibitors) as a Specified Substance. Anastrozole is one of the named compounds in the canonical 2026 WADA Prohibited List Section S4.1 (the Aromatase Inhibitors subsection of S4 Hormone and Metabolic Modulators).[⁶] Specified Substance status means a positive test triggers a reduced sanction range vs non-Specified Substances, but the compound is still prohibited at all times — in-competition and out-of-competition. This is the first S4 listing in the Vialwise library (other entries are listed under S2 peptide hormones / growth factors, S1 anabolic androgenic steroids, or are negative-listings). Researchers competing in any WADA-tested sport will test positive on anastrozole and should plan their compliance accordingly.

Quick reference

Compound class	Third-generation non-steroidal selective aromatase inhibitor. Small molecule (MW 293 Da). Not a peptide.
Common formulation	film-coated tablet (Arimidex and generic equivalents). Pharmacy-compounded sub-1-mg capsules also available for off-label men's-health use.
Frequency	Daily (FDA label) or 2–3× weekly (research-community men's-health off-label use), titrated to lab response.
Half-life	~40–50 hours mean terminal elimination half-life (postmenopausal women PK studies). Steady state achieved within 7–10 days of continuous administration with ~3.5-fold accumulation.[¹]
Route	Oral.
Onset of action	Plasma C_max within ~2 hours of dosing under fasted conditions. Maximum estradiol suppression typically within 3–4 days. Aromatase inhibition: 96.7–97.3% in humans (near-maximal); 98.1% (no meaningful additional suppression beyond).[¹]
Pharmacokinetics	Linear PK across dose range. ~85% hepatic metabolism (primary route), ~11% renal excretion. Estradiol suppression ≥85% in postmenopausal women on.

In depth

Anastrozole is a third-generation non-steroidal selective aromatase inhibitor, developed by Zeneca (now AstraZeneca) under development codes ICI-D1033 and ZD1033 in the late 1980s and early 1990s. The compound was approved by the FDA on December 27, 1995, under NDA 020541 (Arimidex) for treatment of advanced breast cancer in postmenopausal women whose disease had progressed on tamoxifen.[¹] Subsequent FDA approval expansions added first-line metastatic breast cancer (2000) and adjuvant treatment of early-stage hormone-receptor-positive breast cancer in postmenopausal women (2005, supported by the ATAC trial).[²]

Mechanism. Anastrozole reversibly binds and inactivates the cytochrome P450 enzyme aromatase (CYP19A1), the enzyme that catalyzes the final step in estrogen biosynthesis: conversion of androstenedione → estrone, and testosterone → estradiol. Aromatase is expressed in multiple tissues — including adipose tissue (the dominant source of estrogen in postmenopausal women and in men), gonads, brain, breast, and bone. Anastrozole's mechanism is selective: it does not bind glucocorticoid, mineralocorticoid, androgen, or progestin receptors directly. In men, blocking aromatase reduces conversion of testosterone to estradiol, raising the testosterone:estradiol ratio. This is the mechanistic rationale for off-label use in men with hypogonadism (where reduced peripheral estradiol may relieve negative feedback at the hypothalamus and pituitary, increasing endogenous LH and downstream testosterone production) and as a TRT-adjunct (where suppressing aromatization of supplemental testosterone reduces estradiol elevation that may produce side effects like gynecomastia, water retention, or mood changes).

FDA-approved evidence base (postmenopausal breast cancer). The pivotal trial supporting modern adjuvant breast cancer indications is ATAC (Arimidex, Tamoxifen, Alone or in Combination), a phase 3 randomized trial in 9,366 postmenopausal women with localized hormone-receptor-positive early breast cancer. First results published in *The Lancet* in 2002 reported anastrozole monotherapy was superior to tamoxifen in disease-free survival, time to recurrence, and contralateral breast cancer prevention.[²] The 100-month and 10-year analyses (Forbes et al. 2008; Cuzick et al. 2010) confirmed sustained efficacy and characterized the long-term safety profile.[³] The ATAC trial established anastrozole as the standard adjuvant therapy for hormone-receptor-positive postmenopausal early breast cancer for the past 20+ years.

Off-label use in men — published evidence base. Off-label use of anastrozole in men is widespread despite the absence of FDA approval. The published RCT-grade evidence in men is limited but consistent in its key finding: anastrozole reliably normalizes serum testosterone in older hypogonadal men, but does not consistently improve clinical outcomes (body composition, strength, bone, sexual function).

- Leder et al. 2004 (*JCEM*, n=37 elderly men with serum T <350 ng/dL): 12 weeks of anastrozole daily or twice weekly increased mean total testosterone from baseline ~370 ng/dL to ~520–570 ng/dL (within the youthful normal range) and modestly decreased serum estradiol.[⁴] Demonstrated proof-of-mechanism but did not test clinical endpoints. - Burnett-Bowie et al. 2009 (*Clin Endocrinol*, n=88 men ≥60 with hypogonadism symptoms): 12-month RCT of anastrozole daily vs placebo. Testosterone normalized; estradiol decreased; but body composition, strength, PSA, BPH symptoms, hematocrit, and lipid markers did not improve.[⁵] The most-cited single citation establishing the clinical-utility gap. - Tan & Pu 2010 (epilepsy + hypogonadism); Burnett-Bowie et al. 2009b (bone metabolism in elderly men); and the systematic review and meta-analysis of aromatase inhibitors in obesity- and age-related male hypogonadism.[⁷]

The clinical-utility gap. The Burnett-Bowie 2009 finding — that anastrozole reliably raises testosterone but does not produce body composition, strength, PSA, BPH, hematocrit, or lipid improvements — is the clearest single piece of evidence that "normalizing serum testosterone via aromatase inhibition" is mechanistically real but not necessarily clinically equivalent to direct testosterone replacement. This finding is often missed in research-community discussion of anastrozole as a TRT alternative or adjunct.

TRT-adjunct context. The dominant research-community use case is as an adjunct to ongoing testosterone replacement therapy, where supplemental testosterone increases substrate for aromatase and can produce supraphysiologic estradiol elevation in some men. Estradiol-related side effects in men on TRT can include gynecomastia, water retention, mood changes, and (in research-community lore) reduced libido — though the clinical evidence for the "high-estradiol mood and libido effects" claim is weaker than the gynecomastia claim. Anastrozole TRT-adjunct dosing is highly variable across protocols and is typically titrated to a target serum estradiol range (commonly ~20–30 pg/mL for sensitive assays in men, though the optimal target range is contested in the men's-health literature). None of the major men's-health professional society guidelines (Endocrine Society Bhasin 2018, AUA Mulhall 2018) recommend routine AI co-administration with TRT — the recommendation is to monitor for clinical estrogen-excess symptoms and treat selectively if symptomatic, not prophylactically.

Regulatory status (US). Anastrozole is FDA-approved exclusively for postmenopausal breast cancer (advanced, first-line metastatic, and adjuvant early-stage in hormone-receptor-positive disease). All other uses — including all use in men — are off-label. Off-label prescribing is legal in the US under standard FDA prescribing-authority framework but is not supported by FDA-approved labeling and is outside professional society guidelines for men's hypogonadism management. Anastrozole is not DEA-scheduled — distinct from testosterone (Schedule III) — and does not require a controlled-substance prescription. Not compounded under the recent 503A bulks list controversy that affected several peptides — anastrozole is a small-molecule FDA-approved drug with multiple generic manufacturers, distinct regulatory category from research peptides.

Regulatory status (sport — WADA). Anastrozole is explicitly named under Section S4.1 (Aromatase Inhibitors) of the 2026 WADA Prohibited List as a Specified Substance, alongside other aromatase inhibitors (letrozole, exemestane, formestane, testolactone, aminoglutethimide).[⁶] This is the first S4 listing in the Vialwise library — testosterone is S1 (Anabolic Androgenic Steroids), most peptides are S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), and the negative-listing entries are absent from the prohibited list entirely. Specified Substance status under WADA's framework means a positive test can trigger a reduced sanction range (down to a reprimand and no period of ineligibility, in cases where the athlete establishes that the substance was not intended to enhance performance) — but the compound remains prohibited at all times, in-competition and out-of-competition.

Common research interests. Despite the off-label status, anastrozole is among the most-used adjuncts in research-community TRT contexts: - TRT-adjunct estradiol management — the dominant research-community use case. Co-administered with weekly or twice-weekly testosterone injections to manage aromatization-driven E2 elevation. - Off-label hypogonadism management as an alternative to TRT — used in men who want to raise endogenous testosterone without exogenous T administration. Evidence supports proof-of-mechanism (T raises) but not clinical outcomes (Burnett-Bowie 2009).[⁵] - Off-label male infertility management — used in subfertile hypogonadal men, particularly those with BMI ≥25 (where adipose-tissue aromatization elevates baseline E2). A frequently cited "Cleveland Clinic 2024" infertility source cannot be located in the published literature and does not support that framing. A 2024 systematic review and network meta-analysis of 14 RCTs in 1,342 men concluded there is insufficient evidence to support routine use of clomiphene, tamoxifen or aromatase inhibitors to improve semen parameters in male infertility.[⁸] - Pubertal gynecomastia (off-label) — a 2009 PK/PD study in pubertal boys with recent-onset gynecomastia characterized the dose-response.

Reported side effects

Commonly reported

Joint pain / arthralgia — the most-cited side effect; ATAC reported joint symptoms at higher rate with anastrozole vs tamoxifen
Hot flashes — common; typically mild-to-moderate
Bone density loss / osteoporosis risk — well-documented over multi-year exposure; ATAC long-term data showed increased fracture risk vs tamoxifen
Mood symptoms (depression, irritability) — reported; class effect for AIs
Vaginal dryness — common in postmenopausal women; not relevant to male users
Mild dyslipidemia — modest LDL/HDL changes over multi-year exposure
Fatigue, headache, nausea — generally mild
Endometrial cancer risk reduced vs tamoxifen (ATAC) — this is a relative-risk comparison vs tamoxifen, not an absolute reduction vs untreated; relevant only in the breast-cancer comparator context
Joint pain / arthralgia — same class effect; reported in men as well as women
Crashed estradiol symptoms when E2 falls too low: joint pain, libido suppression, erectile dysfunction, mood symptoms, sleep disruption — these are research-community-recognized symptoms of over-suppression and are reversible with dose reduction or discontinuation
Bone density loss — Burnett-Bowie 2009b reported bone-marker changes in elderly hypogonadal men over 12 months[⁵]
Mood symptoms — reported; class effect
Long-term safety in men is essentially unknown beyond 1–2 years. The breast-cancer literature has multi-year ATAC follow-up; the men's-health literature does not. Researchers using anastrozole continuously over years should be explicit with themselves about this gap.
Cardiovascular effects in men — the ATAC trial in postmenopausal women showed modest cardiovascular signal differences vs tamoxifen but in a population with different baseline cardiovascular risk than the men's-health off-label-use cohort. CV outcomes in men on long-term anastrozole are not characterized in published RCTs.
Fertility considerations — anastrozole's effect on raising LH/FSH/T while reducing E2 is the basis for the off-label male-infertility use case, but the long-term fertility implications of multi-year off-label use are not characterized.

Contraindications and warnings

Pregnancy — Category D / fetal harm warning. Anastrozole produced embryo-fetal toxicities at doses 9× human clinical exposure (rats) and pregnancy failure at doses ≥16× human dose (rabbits). Females of reproductive potential should use effective contraception during and after treatment.

Hypersensitivity to anastrozole or any product excipient — anaphylaxis, angioedema, urticaria reported.

Premenopausal women — anastrozole's pharmacology in premenopausal women (with active ovarian aromatase) differs substantially from postmenopausal women; not an FDA-approved use case.

Bone density — multi-year exposure produces measurable bone density loss in the breast-cancer literature; baseline DEXA scan and serial bone density monitoring are appropriate for sustained use, including off-label men's-health use.

Lipids — modest dyslipidemia reported in long-term breast-cancer follow-up; lipid monitoring appropriate.

Concurrent estrogen therapy — pharmacologic antagonism; not recommended.

Concurrent tamoxifen — inferior combination per ATAC; not recommended.

Hepatic impairment — severe hepatic impairment (Child-Pugh C) not studied; use caution.

Lactation — not known whether anastrozole is excreted in human milk; advise against breastfeeding.

Regulatory note (US): FDA-approved for postmenopausal breast cancer only. All use in men is off-label. Generic anastrozole is widely available since 2010 patent expiration. Standard prescription required (not DEA-scheduled).

Regulatory note (sport): WADA-banned in regulated sport — explicitly named under Section S4.1 (Aromatase Inhibitors) of the 2026 Prohibited List as a Specified Substance.[⁶]

Not DEA-scheduled.

Not subject to the 503A bulks list controversy that affected several peptides — anastrozole is a small-molecule FDA-approved drug.

Key terms

Aromatase inhibitor: A drug that blocks the aromatase enzyme, which converts androgens into estrogen, thereby lowering estrogen levels.
Off-label use: Use of an approved drug for a condition or population not listed on its FDA-approved label.
Estradiol: The main form of estrogen; relevant in men because some testosterone is converted to estradiol.
Testosterone replacement therapy (TRT): Medically supervised use of testosterone to treat men with diagnosed low testosterone.

Sources

Related entries

Testosterone — discussed together in this entry's stacks section
HCG (Human Chorionic Gonadotropin) — discussed together in this entry's stacks section
Tamoxifen — discussed together in this entry's stacks section
Exemestane — same mechanism class
Letrozole — same mechanism class